Recombinant Human ACSM3 293 Cell Lysate

• Cat.No.: ACSM3-9070HCL

Specification

• Description: Antigen standard for acyl-CoA synthetase medium-chain family member 3 (ACSM3), transcript variant 2 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ACSM3 acyl-CoA synthetase medium-chain family member 3 [ Homo sapiens ]
• Official Symbol: ACSM3
• Synonyms: ACSM3; acyl-CoA synthetase medium-chain family member 3; SA (rat hypertension associated) homolog , SA hypertension associated homolog (rat) , SAH; acyl-coenzyme A synthetase ACSM3, mitochondrial; SA; protein SA homolog; butyrate--CoA ligase 3; butyryl-coenzyme A synthetase 3; SA hypertension-associated homolog; middle-chain acyl-CoA synthetase 3; SA (rat hypertension-associated) homolog; SAH
• Gene ID: 6296
• mRNA Refseq: NM_005622
• Protein Refseq: NP_005613
• MIM: 145505
• UniProt ID: Q53FZ2
• Chromosome Location: 16p13.11
• Pathway: Butanoate metabolism, organism-specific biosystem; Butanoate metabolism, conserved biosystem; Metabolic pathways, organism-specific biosystem
• Function: ATP binding; butyrate-CoA ligase activity; fatty acid ligase activity; ligase activity; metal ion binding; molecular_function; nucleotide binding

Reviews

04/24/2022

Its reliability allows us to generate robust data and draw meaningful conclusions in our experiments.

03/10/2021

Working with this protein is a breeze! It's like having a friendly assistant in the lab, always ready to lend a helping hand.

09/23/2020

Its high purity, stability, and functionality have surpassed our expectations, enabling precise and rigorous experimentation.

01/14/2020

Excellent customer service combined with top-notch quality. Worth every penny

02/22/2018

The manufacturer provides comprehensive after-sales service, and I am very satisfied with this.

Q&As

What is the potential of ACSM3 as a therapeutic target for metabolic disorders and cancer, and what challenges remain in developing effective ACSM3 inhibitors and activators?

ACSM3 is a potential therapeutic target for metabolic disorders and cancer, but challenges remain in developing effective ACSM3 inhibitors and activators. These include issues with specificity, toxicity, and off-target effects, as well as the need for better understanding of ACSM3 function in different tissues and disease contexts.

How is ACSM3 expression regulated in different tissues, and what factors control its activity?

ACSM3 expression is regulated by a variety of factors, including dietary and hormonal cues, transcriptional and epigenetic regulation, and post-transcriptional modifications such as phosphorylation and ubiquitination.

What is the effect of ACSM3-mediated acylation on protein function and stability, and how does this contribute to cellular signaling and regulation?

ACSM3-mediated acylation can affect protein function and stability, as well as subcellular localization and interaction with other proteins.

How does ACSM3 interact with other lipid metabolism-related enzymes and transporters, such as fatty acid-binding protein (FABP) and carnitine palmitoyltransferase 1 (CPT1)?

ACSM3 interacts with fatty acid-binding protein (FABP) and carnitine palmitoyltransferase 1 (CPT1), both of which are involved in the transport and utilization of fatty acids in cells.

How does ACSM3 interact with other proteins involved in lipid metabolism and transport, such as ATP-binding cassette transporter A1 (ABCA1) and sterol regulatory element-binding protein 1 (SREBP-1)?

ACSM3 interacts with ATP-binding cassette transporter A1 (ABCA1) and sterol regulatory element-binding protein 1 (SREBP-1), both of which are involved in lipid metabolism and transport.

What is the role of ACSM3 in fatty acid metabolism, and how does it contribute to energy homeostasis in cells?

ACSM3 plays a role in the transport and utilization of long-chain fatty acids in mitochondria and peroxisomes, which contributes to energy production and lipid homeostasis. It is also involved in regulating lipid droplet dynamics and the turnover of stored lipids in adipocytes and other cells.

What is the effect of ACSM3 deficiency or overexpression on energy metabolism, lipid accumulation, and insulin sensitivity in different tissues?

ACSM3 deficiency or overexpression can lead to changes in energy metabolism, lipid accumulation, and insulin sensitivity in different tissues, which can contribute to metabolic disorders such as obesity and diabetes.

How does ACSM3 contribute to the regulation of inflammatory responses in metabolic and immune-related pathways?

ACSM3 is implicated in the regulation of inflammatory responses in metabolic and immune-related pathways, particularly in the context of obesity and insulin resistance. It has been shown to modulate the activation of toll-like receptor 4 (TLR4) and the NLRP3 inflammasome in macrophages and other immune cells.

What is the effect of ACSM3 inhibition on cellular proliferation and apoptosis in cancer cells?

ACSM3 inhibition has been shown to induce apoptosis and inhibit proliferation in cancer cells, suggesting a potential therapeutic target for cancer treatment.

What is the effect of genetic polymorphisms in ACSM3 on its expression and activity, and how do these variations contribute to disease susceptibility?

Genetic polymorphisms in ACSM3 have been associated with altered expression and activity of the protein, as well as with increased risk of metabolic disorders such as obesity and type 2 diabetes.